Lung cancer target treatment
The targeted treatment of lung cancer is an accurate treatment for patients with lung cancer and is important. It’s based primarily on specific molecular targets for lung cancer cells. In the course of developing lung cancer cells, there are a number of genetic variations that lead to over-expression or abnormal functioning of certain proteins, which have become targets for drug-oriented effects. Common skin growth factor (EGFR) gene mutations, intertransformation lymphoma enzyme (ALK) gene recasting, etc. Target-oriented drugs can be specifically identified and combined with these targets, which precisely interferes with key links such as the growth, growth and transfer of cancer cells, thus inhibiting the development of the tumor and even reducing it, while damage to normal cells is relatively small. • Drugs commonly used and targeted EGFR: for patients with EGFR genetic mutation, common drugs are Gibertini, Erodini, Afatini, Ositini, etc. These drugs can be effective in inhibiting the activity of the EGFR protein and blocking the transmission of growth signals to cancer cells. • Alk Targeted Medicines: For patients re-engineered by the Alk, drugs such as Kratini, Alecini and Seritini can work on Alkprotein to prevent its abnormal functioning and thus control the growth of the tumor. • ROS1 Targeted Drugs: Some lung cancer patients are genetically integrated with ROS1 and the corresponding target drug, such as khakitini, can be treated for this target. Advantages • High accuracy: A specific target that can accurately affect a cancer cell, as with a precise target, has a small impact on a normal cell, often with less side effects than chemotherapy, and is more resistant to patients. For example, chemotherapy can lead to severe loss of hair, vomiting, etc., while the target is relatively light to treat these symptoms. • Better treatment: within the appropriate group of patients, the target-oriented treatment can significantly prolong the patient’s lifespan, improve the quality of life of the patient, effectively control the progress of lung cancer and, in some cases, even reduce the tumor. • Limited number of people to apply: not all lung cancer patients are suitable for target treatment, but only those who have detected a corresponding target can benefit from it, such as those in specific situations such as EGFR gene mutation or ANK re-engineering. Without these targets, target-oriented treatment may be ineffective. • Drug resistance: As the time of treatment passes, some patients experience drug resistance, i.e., the target that was effective is gradually losing effect and cancer cells start to grow and spread again. This requires further testing to find new targets or replace treatment options. The use of lung cancer targets has given new hope to the treatment of lung cancer patients, especially those with specific targets, but there are still some problems to be addressed, and their efficacy and application are expected to increase further as research continues. The long road to the fight against tumours requires not only constant and in-depth research by medical scientists and the development of more and more effective treatments, but also the concerted efforts of society as a whole. The Government should invest more in oncology research and promote progress in medical research; medical institutions should improve the level of diagnosis and treatment of oncology and provide better medical care for patients; and the public should develop good living habits, enhance self-health awareness, minimize the effects of tumour causes and reduce the risk of tumours. Only then can we achieve greater victory in this difficult struggle against tumours, freeing more patients from the shadow of tumours and reaccepting healthy lives.
